Ehsani Amir Houshang; Noormohammadpour Pedram; Nasiri Nafiseh; Faraz Parastoo Tavasoli; Goodarzi Azadeh
Volume 19, Issue 2 , 2016, , Pages 45-49
Abstract
Background: Approximately 0.77% to 2% of cutaneous ulcers and post-burn scars will develop malignant degeneration. When squamous cell carcinoma (SCC) emerges in a chronic scar or ulcer, it often is referred to as Marjolin’s ulcer (MU). Methods: This cross-sectional study assessed demographic information ...
Read More
Background: Approximately 0.77% to 2% of cutaneous ulcers and post-burn scars will develop malignant degeneration. When squamous cell carcinoma (SCC) emerges in a chronic scar or ulcer, it often is referred to as Marjolin’s ulcer (MU). Methods: This cross-sectional study assessed demographic information and pathological features of MU in Razi Hospital during 2009 to 2014. We reviewed 5150 chronic scar/ulcer cases and found 30 MU cases. Results: Patients had an average age of 59.2±19.9 years. Most cases were males Among 30 cases of MU, well-differential SCC accounted for 43.3% of cases. Moderately-differentiated SCC comprised 13.3% of cases, whereas there was invasive SCC in 10% of MUs. Only 3.3% of patients showed poorly-differentiated SCC and 9 (30%) had undifferentiated SCC. The average latency between burn and malignancy was 32.4±18.5 years In the majority (90%) of cases, the initial injury was a burn. The lower and upper limbs comprised 53.3% and 26.7% of cases, respectively. There was one case with a history of melanoma. Among the 4 measured concurrent risk factors for malignancy, sun exposure was the most prevalent. Conclusion: Since there is a high possibility of SCC formation in burn lesions and other identical lesions, rapid follow-up and appropriate treatment in acute burn lesions is necessary.
Hallaji Zahra; Ehsani Amir Houshang; Noormohammadopoor Pedram; Mansouri Parham
Volume 12, Issue 2 , 2009, , Pages 60-63
Abstract
Background: Psoriasis is a chronic inflammatory skin disease that is estimated to affect 0.6% to 4.8% of the general population. The optimum number of NB-UVB phototherapy sessions is yet to be determined. The aim of this study was to compare therapeutic effects of NB-UVB in treating chronic plaque type ...
Read More
Background: Psoriasis is a chronic inflammatory skin disease that is estimated to affect 0.6% to 4.8% of the general population. The optimum number of NB-UVB phototherapy sessions is yet to be determined. The aim of this study was to compare therapeutic effects of NB-UVB in treating chronic plaque type psoriasis three times weekly vs. five times weekly. Materials and Methods: This study was designed as a single-blinded randomized controlled trial. Patients with chronic plaque type psoriasis who were candidates for phototherapy were randomized in two groups, one group received NB-UVB three times a week (group A) while the other group received the same treatment five times a week (group B) . Patients’ PASI score was determined before commencing the study and after 12 weeks of treatment. At the end of the study, response rate, PASI score of patients and total dose of UVB per patient were determined. Results: A total of 47 patients were enrolled. Thirty two patients (19 in group A, 13 in group B) completed the study. Total response rate was 71.9% after 12 weeks of treatment (23 out of 32 patients) while nine patients (28.1%) had no response. Response rate was 78.9 % (15 out of 19) in group A Vs. 61.5% (8 out of 13 patients) in group B (p>0.05). Total UVB dose received, treatment sessions, erythema and final PASI score was lower in group A (p>0.05). Conclusion: With similar therapeutic effects, it seems that three times a week regimen may be superior to five times a week for its lower total UVB dose received and higher safety profile.
Ehsani Amir Houshang; Hosseini Mahboobeh-Sadat; Lajvardi Vahideh-Sadat
Volume 10, Issue 2 , 2007, , Pages 142-156
Abstract
Erythromycin was the first macolide discovered in 1952. In 1990s new macrolides including clarithromycin, azithromycin, and dirithromycin were introduced to the market. We provide a review of their structure, pharmacokinetics, mechanisms of action, and indications in dermatology.
Read More
Erythromycin was the first macolide discovered in 1952. In 1990s new macrolides including clarithromycin, azithromycin, and dirithromycin were introduced to the market. We provide a review of their structure, pharmacokinetics, mechanisms of action, and indications in dermatology.
